Earnings ·
Acrivon Therapeutics reported second quarter 2026 financial results with a net loss of $18.0 million, compared to…
ACRVAcrivon Therapeutics, Inc.
Acrivon Therapeutics reported second quarter 2026 financial results with a net loss of $18.0 million, compared to $21.0 million in the prior year period. Research and development expenses decreased to $13.8 million from $16.2 million, while general and administrative expenses fell to $4.8 million from $6.5 million. The company held cash, cash equivalents, and marketable securities of $90.0 million as of June 30, 2026, which is expected to fund operations into the fourth quarter of 2027. Clinically, ACR-368 dosing continues in its Phase 2b study for serous endometrial cancer, with a prespecified interim analysis anticipated in the second half of 2026. Additionally, ACR-2316 has advanced into the randomized dose expansion phase of its Phase 1/2 trial, showing durable single-agent activity and a favorable safety profile across multiple tumor types.